Ascendis Pharma A (ASND) Capital Expenditures (2014 - 2024)

Ascendis Pharma A has reported Capital Expenditures for 11 years, with the latest figure at -$512868.5 in Q3 2024.

• Quarterly Capital Expenditures rose 51.73% year-over-year to -$512868.5 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was -$1.0 million (up 84.33% YoY) and the FY2023 annual result came in at -$2.6 million, up 82.7% from the prior year.
• Capital Expenditures retreated to -$512868.5 in Q3 2024 per ASND's latest filing, from -$368295.6 in the prior quarter.
• Over five years, Capital Expenditures peaked at $48.7 million in Q4 2021 and troughed at -$13.3 million in Q3 2021.
• A 5-year average of $1.7 million and a median of -$3.2 million in 2022 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 315.62% in 2020, down 1344.86% in 2020.
• Over 5 years, Capital Expenditures stood at $42.3 million in 2020, then increased by 15.31% to $48.7 million in 2021, then plunged by 107.92% to -$3.9 million in 2022, then jumped by 101.76% to $67784.2 in 2023, then plunged by 856.62% to -$512868.5 in 2024.
• According to Business Quant data, Capital Expenditures over the past three periods registered -$512868.5, -$368295.6, and -$216186.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.